Anti-TIGIT Therapy: Overview of Current Clinical Evidence and Key Ongoing Trials

In this episode, Jyoti D. Patel, MD, and Ani Balmanoukian, MD, discuss several studies investigating agents targeting TIGIT, an emerging immune checkpoint target with promising results in PD-L1-positive NSCLC. The episode includes a review of phase II data on the use of tiragolumab plus atezolizumab in NSCLC, the use of PD-L1 as a marker of response, the potential role of anti-TIGIT therapies in solid tumors, and ongoing trials in lung cancer including SKYSCRAPER-01, SKYSCRAPER-02, SKYSCRAPER-03, and SKYSCRAPER-05. 

Presenters:

Jyoti D. Patel, MD
Professor of Medicine
Division of Hematology and Oncology
Medical Director for Thoracic Oncology
Assistant Director for Clinical Research
Associate Vice Chair of Clinical Research
Department of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois 

Ani  Balmanoukian, MD
Director of Thoracic Oncology
Medical Oncology
The Angeles Clinic and Research Institute, 
a Cedars-Sinai Affiliate
Los Angeles, California

Link to the complete program, including an online text module with downloadable slidesets, ClinicalThought commentaries, and an additional podcast on this topic:
https://bit.ly/38qVCH7

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.